should diseases
Conditions
Interventions
Group R:ropivacaine for brachial plexus nerve block
Group DR:dexmedetomidine added to ropivacaine for brachial plexus nerve bloc
Sponsors
The First People's Hospital of Lianyungang
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Elective shoulder arthroscopic surgery; 2. American Association of Anesthesiologists (ASA) patient classification I~II; 3. Aged 18 to 65 years, regardless of gender; 4. Written consent was obtained after informing the participants about the nature, scope and risks related to the study.
Exclusion criteria
Exclusion criteria: 1. Refused to accept brachial plexus block; 2. BMI > 30Kg/m2; 3. History of severe cardiopulmonary disease, liver and kidney failure, and uncontrolled diabetes; 4. Allergic to any of the study drug; 5. Contraindications to brachial plexus block (coagulopathy or local infection).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| duration of postoperative analgesia; | — |
Secondary
| Measure | Time frame |
|---|---|
| VAS;frequency of PCA pressed;24h total sufentanil consumption;first time of PCA pressed;patient satisfaction for the quality of analgesia; | — |
Countries
China
Contacts
Public ContactLuan Hengfei
The First People's Hospital of Lianyungang
Outcome results
None listed